{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:43Z","timestamp":1790742043675,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL152090"],"award-info":[{"award-number":["R01HL152090"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, which redirect T-cells to tumor antigens, have immensely benefitted patients with relapsed\/refractory B-cell cancers. How these therapies differ in cardiotoxicity is underexplored. We used the World Health Organization pharmacovigilance database, VigiBase, to compare cardiotoxicity profiles between CD19-targeted CAR-T therapy and blinatumomab (a CD19\/CD3-targeted bispecific T-cell engager).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Safety reports in VigiBase were filtered for diffuse large B-cell lymphoma (DLBCL, n\u2009=\u200917,479) and acute lymphocytic leukemia (ALL, n\u2009=\u200928,803) for all adverse reactions. Data were further filtered for patients taking CAR-T therapy or blinatumomab. Reporting odds ratios (ROR) and fatality rates were compared between CAR-T cell products (e.g. tisagenlecleucel and axicabtagene ciloleucel), and between CAR-T therapy and blinatumomab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tisagenlecleucel is associated with cardiac failure (IC<jats:sub>025<\/jats:sub>\u2009=\u20090.366) with fatality rates of 85.7% and 80.0% in DLBCL and pediatric ALL patients respectively. For DLBCL patients, axicabtagene ciloleucel has greater reporting for hypotension than tisagenlecleucel (ROR: 2.54; 95% CI: 1.28\u20135.03; p\u2009=\u20090.012), but tisagenlecleucel has higher fatality rates for hypotension than axicabtagene ciloleucel [50.0% (tisagenlecleucel) vs 5.6% (axicabtagene ciloleucel); p\u2009&lt;\u20090.001]. Blinatumomab and tisagenlecleucel have similar fatality rates for hypotension in pediatric ALL patients [34.7% (tisagenlecleucel) vs 20.0% (blinatumomab); p\u2009=\u20090.66].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tisagenlecleucel is associated with severe and fatal adverse cardiac events, with higher fatality rates for hypotension compared to axicabtagene ciloleucel in DLBCL patients, but similar hypotension fatality rates compared to blinatumomab in pediatric ALL patients. Effective management necessitates experienced physicians, including cardio-oncologists, skilled in interdisciplinary approaches to manage these toxicities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s43856-024-00540-9","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T10:04:04Z","timestamp":1718273044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers"],"prefix":"10.1038","volume":"4","author":[{"given":"Badri","family":"Karthikeyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha Shyam","family":"Sunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-5554","authenticated-orcid":false,"given":"Scott H.","family":"Olejniczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswati","family":"Pokharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0476-2523","authenticated-orcid":false,"given":"Umesh C.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"540_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya, S. & Barta, S. K. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am. J. Hematol. 96, 617\u2013629 (2021).","journal-title":"Am. J. Hematol."},{"key":"540_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7, e577 (2017).","journal-title":"Blood Cancer J."},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien, T. W. & Tedder, T. F. B lymphocytes: how they develop and function. Blood 112, 1570\u20131580 (2008).","journal-title":"Blood"},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone, M. C. et al. Engineering enhanced CAR T-cells for improved cancer therapy. Nat. Cancer 2, 780\u2013793 (2021).","journal-title":"Nat. Cancer"},{"key":"540_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"540_CR6","doi-asserted-by":"publisher","unstructured":"Honikel, M. M. & Olejniczak, S. H. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules 12, https:\/\/doi.org\/10.3390\/biom12091303 (2022).","DOI":"10.3390\/biom12091303"},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/17474086.2022.2044778","volume":"15","author":"S Perrone","year":"2022","unstructured":"Perrone, S., Lopedote, P., Levis, M., Di Rocco, A. & Smith, S. D. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. Expert Rev. Hematol. 15, 215\u2013232 (2022).","journal-title":"Expert Rev. Hematol."},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129, 1039\u20131041 (2017).","journal-title":"Blood"},{"key":"540_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"540_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.619650","volume":"8","author":"S Xu","year":"2021","unstructured":"Xu, S., Sharma, U. C., Tuttle, C. & Pokharel, S. Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Front. Cardiovasc. Med. 8, 619650 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"540_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.930797","volume":"9","author":"V Quagliariello","year":"2022","unstructured":"Quagliariello, V. et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front Cardiovasc. Med. 9, 930797 (2022).","journal-title":"Front Cardiovasc. Med."},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs-past developments and future directions. Immunol. Rev. 270, 193\u2013208 (2016).","journal-title":"Immunol. Rev."},{"key":"540_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment. Cancer Discov. 8, 924\u2013934 (2018).","journal-title":"Cancer Discov."},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 14, 75 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"540_CR15","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey, N. & Porter, D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol. Blood Marrow Transpl. 25, e123\u2013e127 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck, M., Michel, L., Lin, Y., Herrmann, J. & Rassaf, T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur. Heart J. 43, 1928\u20131940 (2022).","journal-title":"Eur. Heart J."},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"540_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi, R. M. et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J. Am. Coll. Cardiol. 74, 3099\u20133108 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev. Clin. Immunol. 15, 813\u2013822 (2019).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"Ganatra, S. et al. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. J. Am. Coll. Cardiol. 74, 3153\u20133163 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf. J.: DIJ \/ Drug Inf. Assoc. 42, 409\u2013419 (2008).","journal-title":"Drug Inf. J.: DIJ \/ Drug Inf. Assoc."},{"key":"540_CR24","unstructured":"MedDRA. Multiaxiality, https:\/\/www.meddra.org\/multiaxiality (2022)."},{"key":"540_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2011","unstructured":"Nor\u00e9n, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22, 57\u201369 (2011).","journal-title":"Stat. Methods Med. Res."},{"key":"540_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"540_CR28","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"540_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"540_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"540_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"540_CR32","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"540_CR33","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg, A. et al. Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia. J. Clin. Oncol. 34, 4381\u20134389 (2016).","journal-title":"J. Clin. Oncol."},{"key":"540_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli, F. et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Jama 325, 843\u2013854, (2021).","journal-title":"Jama"},{"key":"540_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger, N., Bond, D. & Jaglowski, S. CAR T-cell therapy for B-cell lymphoma. Curr. Probl. Cancer 46, 100826 (2022).","journal-title":"Curr. Probl. Cancer"},{"key":"540_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan, M., Manoochehri, H. & Dama, P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 29, 1080\u20131096 (2022).","journal-title":"Cancer Gene Ther."},{"key":"540_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh, R. H. & Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275\u2013285 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"540_CR38","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","volume":"75","author":"JE Salem","year":"2020","unstructured":"Salem, J. E., Ederhy, S., Lebrun-Vignes, B. & Moslehi, J. J. Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective. J. Am. Coll. Cardiol. 75, 2521\u20132523 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR39","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J. Am. Coll. Cardiol. 78, 1800\u20131813 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"540_CR40","doi-asserted-by":"publisher","first-page":"924208","DOI":"10.3389\/fonc.2022.924208","volume":"12","author":"LR Chen","year":"2022","unstructured":"Chen, L. R. et al. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. Front Oncol. 12, 924208 (2022).","journal-title":"Front Oncol."},{"key":"540_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre, B. et al. Cardiovascular Effects of CAR T Cell Therapy. A Retrospective Study JACC Cardio. Oncol. 2, 193\u2013203 (2020).","journal-title":"A Retrospective Study JACC Cardio. Oncol."},{"key":"540_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"540_CR43","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 5, https:\/\/doi.org\/10.1126\/sciimmunol.aax7969 (2020).","DOI":"10.1126\/sciimmunol.aax7969"},{"key":"540_CR44","doi-asserted-by":"publisher","unstructured":"Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, https:\/\/doi.org\/10.1126\/science.aaz7548 (2020).","DOI":"10.1126\/science.aaz7548"},{"key":"540_CR45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660\u2013665 (2015).","journal-title":"Nature"},{"key":"540_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat. Rev. Immunol. 20, 95\u2013112 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"540_CR47","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"540_CR48","first-page":"598","volume":"4","author":"GA Suero-Abreu","year":"2022","unstructured":"Suero-Abreu, G. A., Zanni, M. V. & Neilan, T. G. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management. JACC: Cardio. Oncol. State\u2013Art. Rev. JACC Cardio. Oncol. 4, 598\u2013615 (2022).","journal-title":"JACC: Cardio. Oncol. State\u2013Art. Rev. JACC Cardio. Oncol."},{"key":"540_CR49","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman, I. et al. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J. Clin. Invest. 117, 2974\u20132982 (2007).","journal-title":"J. Clin. Invest."},{"key":"540_CR50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"DX Bu","year":"2011","unstructured":"Bu, D. X. et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb. Vasc. Biol. 31, 1100\u20131107 (2011).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"540_CR51","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","volume":"168","author":"MM Ewing","year":"2013","unstructured":"Ewing, M. M. et al. T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J. Cardiol. 168, 1965\u20131974 (2013).","journal-title":"Int J. Cardiol."},{"key":"540_CR52","first-page":"5","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell, C. A., Wenzell, C. M. & Advani, A. S. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin. Pharm. 5, 5\u201311, (2013).","journal-title":"Clin. Pharm."},{"key":"540_CR53","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"540_CR54","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055\u20131065 (2022).","journal-title":"Lancet Oncol."},{"key":"540_CR55","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. CAR-T efficacy: is conditioning the key? Blood 133, 1799\u20131800 (2019).","journal-title":"Blood"},{"key":"540_CR56","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncponc0666","volume":"3","author":"P Muranski","year":"2006","unstructured":"Muranski, P. et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat. Clin. Pr. Oncol. 3, 668\u2013681 (2006).","journal-title":"Nat. Clin. Pr. Oncol."},{"key":"540_CR57","doi-asserted-by":"publisher","unstructured":"Buza, V., Rajagopalan, B. & Curtis, A. B. Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 10, https:\/\/doi.org\/10.1161\/circep.117.005443 (2017).","DOI":"10.1161\/circep.117.005443"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00540-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T10:05:01Z","timestamp":1718273101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00540-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}